Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cn21:09 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

Anhui Fuhuang Steel Structure: Merging to position itself in the high-speed vision track, no further expansion in the steel structure business | Company research.

① The head of Anhui Fuhuang Steel Structure's Business stated that there will no longer be significant investments in the steel structure business, and the high-speed vision business will become the focus of the company's development; ② The high-speed vision Industry is a XINXINGCHANYE. From the bid amount, Zhongke Shijie occupies 49% of the Global bid amount for high-speed cameras in December, an increase of 8 percentage points year on year.

cls.cnDec 26, 2024 06:13 ET

This week adds 20 more! China State Construction Engineering Corporation and several other stocks disclosed shareholding and repurchase loan plans, a list of related A-share stocks is provided.

① The acceleration of Share Buyback and Shareholding through refinancing is being implemented, according to incomplete statistics from the Financial Association. As of the time of this report, 20 listed companies have disclosed information related to Share Buyback and refinancing this week (see attached table); ② The controlling shareholder of China State Construction Engineering Corporation has obtained a special loan with the maximum amount not exceeding 1.08 billion yuan. HMT (Xiamen) New Technical Materials Co., Ltd intends to increase its Share Buyback scale, and the next day's closing stock price hit the limit up.

cls.cnDec 21, 2024 02:47 ET

The State-owned Assets Supervision and Administration Commission strengthens market cap management of controlling listed companies; unprofitable central enterprises are expected to gain a competitive edge.

The State Council's State-owned Assets Supervision and Administration Commission recently issued several opinions on improving and strengthening the Market Cap management of centrally held listed companies. It emphasizes the importance of addressing the issue of listed companies trading below net asset value, incorporating the solution to this long-standing problem into the annual key work, guiding long-term undervalued listed companies to formulate and disclose valuation enhancement plans, and supervising their implementation.

cls.cnDec 17, 2024 19:01 ET

It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17, 2024 09:51 ET